Baird analyst David Rescott raised the firm’s price target on iRhythm (IRTC) to $133 from $126 and keeps an Outperform rating on the shares. The firm said there were no surprises in its Q4 beat but 2025 guidance appears conservative and the ZioMCT acceleration is on track.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm price target raised to $135 from $120 at BTIG
- Strong Sales Growth and Strategic Expansion Drive Buy Rating for iRhythm Technologies
- iRhythm price target raised to $104 from $86 at Wells Fargo
- iRhythm Technologies Reports Robust 2024 Growth
- iRhythm sees FY25 revenue $675M-$685M, consensus $679.42M